View Clinical Trial (Medical Research Study)


Clinical Investigation of the LCS® Complete Posterior Stabilized Mobile-bearing Total Knee System - NCT00487565-15260(Clinical Trial 172744)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup

City:  Pittsburgh
State:  
PA
Zip Code: 15260
Conditions: Osteoarthritis - Rheumatoid Arthritis - Post-Traumatic Arthritis - Juvenile Arthritis
Purpose: Prospective, multi-center clinical study to evaluate the clinical outcomes of the posterior stabilized design of the LCS® Complete Mobile-bearing Total Knee System
Study summary: Prospective, multi-center study to evaluate the clinical outcome of posterior stabilized design of LCS® Complete Mobile-Bearing Total Knee System. No comparison group. 12 month enrollment, 12 month post-operative evaluation. Follow-up intervals: Pre-op, 3 month, 6 month, and 12 month.
Criteria: Inclusion Criteria: - M/F - 18-80 - Diagnosis of osteoarthritis, rheumatoid , post-traumatic, inflammatory, juvenile arthritis. - Skeletally mature, sufficient bone stock to seat and support prosthesis - Willing/able return for follow-up. Exclusion Criteria: - History of recent/active joint sepsis, charcot neuropathy, psycho-social disorders, prior knee arthroplasty on affected site, metabolic disorders of calcified tissue - Communicable diseases that may limit follow-up - Medical-legal or workers compensation claims.
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.

Data Source: ClinicalTrials.gov
Date Processed: October 7, 2010
Modifications to
this listing:
Only selected fields are shown, please use the link above to view all information about this clinical trial.